Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Citi Reiterates Buy Rating on Eli Lilly (LLY)
June 25, 2025 5:11 AM UTCCiti analyst Geoff Meacham reiterated a Buy rating and $1,190.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Given compelling data, Lilly and Novo have reframed obesity as a treatable disease, not just a lifestyle/behavior-based condition. The obesity paradigm should further... More
Eli Lilly & Co. (LLY) Declares $1.50 Quarterly Dividend; 0.8% Yield
June 23, 2025 11:37 AM UTCEli Lilly & Co. (NYSE: LLY) declared a quarterly dividend of $1.50 per share, or $6 annualized.
The dividend will be payable on September 10, 2025, to stockholders of record on August 15, 2025, with an ex-dividend date of August 14, 2025.
The annual yield on the dividend is 0.8... More
Evercore ISI Reiterates In Line Rating on Eli Lilly (LLY)
June 23, 2025 11:18 AM UTCEvercore ISI analyst Umar Raffat reiterated an In Line rating on Eli Lilly (NYSE: LLY)
The analyst commented, "I dont think Street was expecting much on weight loss with bimagrumab (which is not a GLP) and it put up 10% weight loss which surprised me in a very good way. On... More
BMO Capital: 'Eli Lilly (LLY) Metabolic Portfolio Shows New Legs at ADA Event'
June 23, 2025 9:46 AM UTCBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $900.00 price target on Eli Lilly (NYSE: LLY).
The analyst commented: "Lilly Metabolic Portfolio Shows New Legs at ADA Event; Lilly, forever one to not rest on its laurels. Full... More
Truist Reiterates Buy Rating on Eli Lilly (LLY) Following OFG Presentation at ADA
June 23, 2025 9:22 AM UTCTruist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $1,038.00 price target on Eli Lilly (NYSE: LLY).
The analyst commented: "We attended the orforglipron (OFG) presentation at ADA, received feedback on the drug from several KOLs present at the conference and also... More
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
June 23, 2025 7:09 AM UTCCantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $975.00 price target on Eli Lilly (NYSE: LLY).
The analyst commented, Lilly notably (1) emphasized eloralintide is a selective amylin receptor agonist (vs. calcitonin receptor agonist), which it believes should offer an improved GI profile potentially offering... More
GLP-1s Should Be First Line To Prevent Heart Disease, Acc Says - Bloomberg
June 20, 2025 10:02 AM UTCGLP-1s Should Be First Line To Prevent Heart Disease, Acc Says - Bloomberg
... More